Bridge Therapeutics, a late development-stage specialty pharmaceutical company, has added Steven Passik PhD to its Scientific Advisory Board, it was reported yesterday.
Dr Passik PhD, Clinical Psychology, is a leader and researcher in pain management and addiction. He has written extensively on the treatment of cancer and AIDS patient's pain management. He has been a principal investigator for numerous clinical trials funded by both pharmaceutical companies and government funded organisations. He has been the recipient of numerous awards for his excellence in clinical research.
Dr Greg Sullivan, chief science officer and founder of Bridge Therapeutics said, 'Dr Passik has a wealth of knowledge on the practical application of pain management in the real world, not just in the clinical setting. I'm excited to see what he will add to Bridge's efforts in developing safer chronic pain treatments.'
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA